Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops orally administered small molecule therapies for severe muscle disorders. The company's business model centers on precision medicine targeting the root causes of diseases driven by abnormal skeletal and cardiac muscle mechanics. Historically, its lead candidate was sevasemten (EDG-5506) for dystrophinopathies like Becker and Duchenne muscular dystrophy. However, in July 2026, Edgewise completed the sale of sevasemten and its muscular dystrophy business to Servier for $1.55 billion upfront and up to $1.1 billion in potential milestones. This transformative transaction shifted the company's strategic focus to its cardiovascular pipeline. Its current lead programs include EDG-7500, a novel cardiac sarcomere modulator in Phase 2 development for hypertrophic cardiomyopathy (HCM), and EDG-15400, a small molecule for heart failure with preserved ejection fraction. As a pre-commercial entity, Edgewise does not yet generate product revenue and relies on its substantial cash reserves—significantly bolstered by the Servier transaction—to fund its clinical trials and operations. The company operates primarily in the United States and competes with other biopharmaceutical firms developing targeted therapies for rare cardiac conditions.
